Rezultati pretraživanja
  1. prije 3 sata
  2. 4. velj

    & researchers use tumor data to calculate efficacy of and predict response to . CIRCULOGENE: One Tube, One Week, Complete Results.

  3. 4. velj

    Today is ! Explore our new Immunology Virtual Issue featuring the latest research on , , cancer & the role of All free to access 👉

  4. 2. velj
  5. 1. velj

    How to make work for more patients? “One culprit behind a poor response to immunotherapy may be the immune system’s own first responders: neutrophils," writes referencing study led by our Dr. McGarry Houghton

  6. 31. sij

    A systematic review of the methods used by RCTs to report health-related quality of life in cancer patients treated with immune finds there is a lack of questionnaires validated for cancer patients treated with :

  7. 29. sij

    Arthroscopy findings in arthritis induced by pembrolizumab: note synovial hypertrophy and hypervascularity

  8. 14. sij

    We are excited to see our review out, which includes a transplant section about all reported work on immune ' use in kidney . Overall incidence of is ~50% with -PD1 and about 35% with -CTLA4.

  9. After analyzing tumor samples from 28 patients with non-small cell , researchers linked a common immune cell with the failure of . The culprit: neutrophils, the most abundant type of white blood cell.

  10. 8. pro 2019.

    What adverse events are there from the use of immune in patients with ? A global group - including our own and - provide the answer, in this new paper in :

  11. : Now a staff clinician at , , MD, PhD was a in 2012. The novel therapies she is developing using & tools include a study of recombinant with .

  12. Potential mechanisms of immune-related adverse events caused by immune .

  13. 13. lip 2019.

    EULAR Recommendations for immune-related adverse events of treatment for cancer OP0165: all that rheumatologists need to know! >LA

  14. work by releasing a natural brake on your immune system so that immune cells called T cells recognize and attack tumors.

  15. 21. svi 2019.

    I can't leave without giving tribute to Dr. James Allison (and his wife Dr. Pam Sharma--my residency friend) for winning the for his work in the discovery of

  16. 19. svi 2019.

    Dr.Theodorescu makes a strong case for functional genomic approaches to identify effective combinations with , winning target DDR2

  17. Enhancing antitumor response by combining immune with chemotherapy in solid tumors

  18. 22. velj 2019.
  19. Experimental pathway shows real potential in treating with . New research from PICI's Jim Allison, PhD, and Padmanee Sharma, MD, PhD . Story via

  20. : Our editors pick some of their favourite from 2018 Rheumatic immune-related adverse events from cancer immunotherapy

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.